Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC).
Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC).
复制标题
DOI：
10.1111/1759-7714.12399
复制
发表时间：
2017-03
期刊：
影响因子：
2.9
通讯作者：
Wang J
中科院分区：
文献类型：
--
作者：
Guo Q;Sun Y;Yu S;Bai H;Zhao J;Zhuo M;Wang J
本研究旨在探索IIIB/IV期肺鳞状细胞癌（SQC）中程序性细胞死亡配体-1（PD-L1）表达和成纤维细胞生长因子受体1（FGFR 1）扩增。分析PD-L1和FGFR 1与临床病理特征、铂类化疗疗效和预后的相关性。本研究从2009年至2014年入组了128例连续III/IV期SQC患者。78例患者接受了含铂化疗。使用免疫组织化学评估PD-L1表达，并应用荧光原位杂交检测FGFR 1扩增。 在61.7%（79/128）的肺SQC患者中检测到PD-L1表达。吸烟者的PD-L1表达率显著高于非吸烟者（分别为66.1%和44.0%，P = 0.042）。PD-L1阴性和阳性患者之间铂类化疗的客观缓解率和疾病控制率无显著差异（分别为43.3%和36.2%，P = 0.434; 80.0%和78.7%，P = 0.840）;然而，PD-L1阴性患者的总生存期显著长于PD-L1阳性患者（41.5 vs. 19.3个月，P = 0.001）。25%（32/128）的患者显示FGFR 1扩增，III期患者的发生率低于IV期患者（分别为17.1% vs. 36.5%，P = 0.013）。总体缓解率、疾病控制率或总生存率之间FGFR 1扩增水平无显著差异。PD-L1表达与FGFR 1扩增之间未观察到相关性（P = 0.916）。 PD-L1表达可能是中国III/IV期SQC患者的预后因素。FGFR 1扩增在晚期SQC患者中更普遍，但不能预测化疗反应。PD-L1表达与FGFR 1扩增之间无明显相关性。
This study was conducted to explore programmed cell death‐ligand‐1 (PD‐L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage IIIB/IV lung squamous cell carcinoma (SQC). Correlations between PD‐L1 and FGFR1, and with clinicopathological characteristics, efficacy of platinum‐based chemotherapy, and prognosis were analyzed. One hundred and twenty‐eight consecutive stage III/IV SQC patients were enrolled in this study from 2009 to 2014. Seventy‐eight patients received platinum‐based chemotherapy. Immunohistochemistry was used to assess PD‐L1 expression and fluorescence in situ hybridization was applied to detect FGFR1 amplification. PD‐L1 expression was detected in 61.7% (79/128) of lung SQC patients. Smokers had significantly higher PD‐L1 expression rates than non‐smokers (66.1% vs. 44.0%, P = 0.042, respectively). The objective response and disease control rates for platinum‐based chemotherapy were not significantly different between PD‐L1 negative and positive patients (43.3% vs. 36.2%, P = 0.434; 80.0% vs. 78.7% P = 0.840, respectively); however, overall survival in PD‐L1‐negative patients was significantly longer than in PD‐L1‐positive patients (41.5 vs. 19.3 months, P = 0.001). Twenty‐five percent (32/128) of patients displayed FGFR1 amplification, with a lower rate in stage III patients compared to stage IV (17.1% vs. 36.5%, P = 0.013, respectively). There was no significant difference in FGFR1 amplification levels between overall response, disease control or overall survival rates. No correlation was observed between PD‐L1 expression and FGFR1 amplification (P = 0.916). PD‐L1 expression may function as a prognostic factor in Chinese stage III/IV SQC patients. FGFR1 amplification is more prevalent in late stage SQC patients but does not predict chemotherapy response. There is no apparent correlation between PD‐L1 expression and FGFR1 amplification.